You can buy or sell Horizon Pharma and other stocks, options, ETFs, and crypto commission-free!
Horizon Pharma plc Ordinary Shares (Ireland), also called Horizon Pharma, is a biopharmaceutical company which is engaged in the research, development and market of pharmaceutical products. The medicines intend to treat arthritis, inflammation and orphan diseases. Read More It distributes its products under the brands such as Actimmune, Buphenyl, Duexis, Krystexxa, Migergot, Pennsaid, Ravicti, Rayos and Vimovo. The company was founded in 2008 and is headquartered in Dublin, Ireland.
52 Week High
52 Week Low
Research And Development
Yahoo FinanceMar 21
Edited Transcript of HZNP earnings conference call or presentation 27-Feb-19 1:00pm GMT
Q4 2018 Horizon Pharma PLC Earnings Call Dublin Mar 21, 2019 (Thomson StreetEvents) -- Edited Transcript of Horizon Pharma PLC earnings conference call or presentation Wednesday, February 27, 2019 at 1:00:00pm GMT TEXT version of Transcript ================================================================================ Corporate Participants ================================================================================ * Paul W. Hoelscher Horizon Pharma plc - Executive VP & CFO * Robert F. Carey ...
Associated PressMar 18
Horizon Pharma plc Wins PR News CSR Award for Partnership with Perspectives Math and Science Academy
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation. This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation. DUBLIN--(BUSINESS WIRE)--Mar 18, 2019--Horizon Pharma plc (Nasdaq: HZNP) announced today that it has won a PR News CSR Award in the Corporation category for its impactful partnership with Chicago-based charter school, Perspectiv...
Yahoo FinanceMar 11
Horizon Pharma plc Announces Closing of Public Offering of Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares
DUBLIN--(BUSINESS WIRE)-- -- Total offering size of $345 million – -- Incremental $200 million borrowing capacity secured under new revolving credit facility -- Horizon Pharma plc (HZNP) today announced the closing of its underwritten public offering of 14,081,632 of its ordinary shares at a price to the public of $24.50 per share. This includes the exercise in full by the underwriters of their option to purchase up to 1,836,734 additional ordinary shares. The estimated net proceeds to the Company from t...
Expected May 8, Pre-Market